Pharmacokinetics and Safety of Long-Acting Release Formulations of Pasireotide (SOM230) in a Male Population Who Are Hyperendemic Hepatitis B/C and Chronic Kidney Disease: An Open-Label, Phase I Study
ConclusionsBoth pasireotide formulations showed dose-proportional pharmacokinetics and 300 –900 μg of SC pasireotide and 20–60 mg LAR pasireotide treatment showed favorable safety profiles and was well-tolerated when administered in male Taiwanese volunteers who are hyperendemic hepatitis B/C and CKD.
Source: European Journal of Drug Metabolism and Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research
More News: Chronic Kidney Disease | Drugs & Pharmacology | Electrocardiogram | Hepatitis | Hepatitis B | Insulin | Laboratory Medicine | Study | Taiwan Health | Urology & Nephrology